Ustekinumab, another biologic with potential to help patients with hidradenitis suppurativa?

Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum

(2016) J.L. Blok et al.   BRITISH JOURNAL OF DERMATOLOGY

Inflammatory Mechanisms in Hidradenitis Suppurativa

(2016) G. Kelly et al.   DERMATOLOGIC CLINICS

Treatment of hidradenitis suppurativa with biologic medications

(2015) Robert A. Lee et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Adalimumab for the Treatment of Moderate to Severe Hidradenitis Suppurativa

(2013) Alexa B. Kimball et al.   ANNALS OF INTERNAL MEDICINE

Preliminary findings suggest hidradenitis suppurativa may be due to defective follicular support

(2013) F.W. Danby et al.   BRITISH JOURNAL OF DERMATOLOGY

Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease

(2012) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: A randomized, double-blind, placebo-controlled crossover trial

(2010) Annika Grant et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Randomized Control Trial for the Treatment of Hidradenitis Suppurativa with a Neodymium-Doped Yttrium Aluminium Garnet Laser

(2009) Emily Tierney et al.   DERMATOLOGIC SURGERY

Hidradenitis suppurativa: A comprehensive review

(2009) Ali Alikhan et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

(2008) Craig L Leonardi et al.   LANCET